A new wave of AI-driven solutions is targeting the complex world of pharmacovigilance, and Graph AI just secured $13.3M in Series A funding to lead the charge. The company has developed the industry's first AI-native Patient Safety Operating System, designed to unify the fragmented landscape for biopharma enterprises and Contract Research Organizations (CROs).
Founded by enterprise technology veterans, Graph AI's system replaces legacy, labor-intensive workflows with a deterministic, inspection-ready AI architecture. It explicitly aligns with stringent regulatory frameworks, including the FDA鈥檚 AI Credibility Assessment Framework and the EU AI Act, offering mathematical reproducibility and absolute data transparency across its comprehensive lifecycle portfolio.














